TrkB modulator OT-003 reduces dopaminergic cell loss, mitochondrial stress, alpha-synuclein aggregation and motor dysfunction in Parkinson’s disease models.
Objective: To assess efficacy and potency of our proprietary lead compound OT-003, an orally bioavailable small molecule Tropomyosin receptor kinase B (TrkB) modulator, in preclinical…Anle138b-P1-02: A randomised, double-blinded, placebo-controlled phase 1b study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of the oligomer modulator anle138b in Parkinson´s disease
Objective: To present first-in-patient data of the oligomer modulator anle138b (TEV-56286, emrusolmin) in patients with Parkinson’s disease (PD). Background: Synucleinopathies such as PD and Multiple…Protective potential of laughter yoga and clapping exercise on stress level and motor functions in Parkinson’s disease patients with type 2 diabetes
Objective: To examine the protective potential of laughter yoga and clapping exercise on blood glucose regulation on stress level and motor functions of PD patients…Neuroprotective properties of arylpiperazine-sulphonamides in an in vitro model of Parkinson’s disease
Objective: To investigate the neuroprotective effects of novel arylpiperazine compounds as measured by viability of SH-SY5Y cells in vitro. Background: Parkinson’s disease (PD) is a…Therapy-associated risk decision making in individuals with multiple system atrophy and Parkinson’s disease, THE YAMSA TRIAL
Objective: This study aimed to quantify the risk willingness of patients suffering from the α-synucleinopathies multiple system atrophy (MSA) and Parkinson's Disease (PD) and identify…Preliminary Report on Neuromelanin-Sensitive MRI Signal change after Allogeneic Bone marrow-derived Mesenchymal Stem Cells therapy: Phase IIa double-blind, randomized controlled trial
Objective: To select the most effective number of repeat doses of mesenchymal stem cells (MSC) delivered intravenously to slow the progression of Parkinson’s disease (PD).…Multicenter, randomized, placebo-controlled, double-blind, parallel-group proof-of-concept study of lixisenatide in patients with early Parkinson’s disease (PD): the LIXIPARK trial (NCT03439943)
Objective: To evaluate the “disease-modifying” effect of lixisenatide as adjunct to antiparkinsonian medications in patients with early PD. Background: Lixisenatide, a glucagon-like peptide 1 receptor…Functional brain network alterations in the prodromal phase of X-linked dystonia-parkinsonism
Objective: To determine whether functional connectivity changes are already present in non-manifesting carriers (NMCs) of the TAF1 gene mutation causing X-linked dystonia-parkinsonism (XDP). Background: XDP…The Critical Path for Parkinson’s Consortium approach to developing consensus recommendations for neuroimaging biomarkers appropriate for use in Parkinson’s disease drug development
Objective: To develop consensus recommendations for neuroimaging biomarkers suitable for use in Parkinson’s disease (PD) drug development. Background: Given the anticipated rise in PD prevalence…Small Molecule Inhibitors for Precise Inhibition of α-Synuclein Oligomer Generation in Parkinson’s Disease (PD)
Objective: To develop small molecule therapeutics for PD that inhibit production of toxic α-synuclein oligomers and reduce aggregate formation, targeting the molecular mechanisms at the…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 19
- Next Page »